Q-omics provides the consensus-scored ICE2P1 profile across patient tissues and cancer cell-line models. ICE2P1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in PCPG. Among the 18 cancer types available for tumor–normal comparison, ICE2P1 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, ICE2P1 RNA expression shows 6,452 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PCPG, BRCA, and STAD as cancer lineages where ICE2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ICE2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ICE2P1 survival associations across molecular data types. ICE2P1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ICE2P1 RNA expression–survival associations across cancer types. High ICE2P1 expression shows unfavorable associations in PCPG, HNSC, MESO, BLCA, COAD and SKCM. The PCPG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify PCPG as the clearest survival context for ICE2P1 RNA expression.
This table summarizes ICE2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ICE2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ICE2P1 shows lower tumor expression in BRCA, UCEC, KIRP, KICH and LUAD and higher tumor expression in COAD. The BRCA box plot shows higher ICE2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.051, t-test p < 0.001).
This table shows molecular features associated with ICE2P1 in patient tissues and cancer cell lines. In patient samples, ICE2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
